A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Study phase (if other): Ib/2

Primary disease category: Cancer

Sponsor: Dynavax

Projected enrollment dates: January 2017 to December 2019

Official study title: A Phase 1b/2, Open-label, Multicenter, Dose-escalation andExpansion Trial of Intratumoral SD-101 in Combination WithPembrolizumab in Patients With Metastatic Melanoma or Recurrentor Metastatic Head and Neck Squamous Cell Carcinoma